Fort Point Capital Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Fort Point Capital Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,299	Closed	-$481K	–	315
2021 Q4	$481K	Sell	4,299 -198	-4%	-$23.9K	0.06%	168
2021 Q3	$565K	Sell	4,497 -83	-2%	-$10.7K	0.08%	126
2021 Q2	$620K	Buy	4,580 +77	+2%	+$10.1K	0.11%	84
2021 Q1	$611K	Sell	4,503 -526	-10%	-$78.8K	0.13%	78
2020 Q4	$708K	Sell	5,029 -54	-1%	-$6.92K	0.16%	73
2020 Q3	$566K	Buy	+5,083	New	+$570K	0.14%	77

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Fort Point Capital Partners's XBI Position: Q1 2022 in Review

Fort Point Capital Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 4,299 shares — an estimated $481K sold.

Fort Point Capital Partners first reported a position in XBI in Q3 2020 and held it in 6 quarters. The position peaked at $708K in Q4 2020. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

Fort Point Capital Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
Fort Point Capital Partners sold 4,299 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $481K.
Fort Point Capital Partners first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and held it in 6 quarters.
Fort Point Capital Partners's State Street SPDR S&P Biotech ETF position peaked at $708K in Q4 2020.
703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Fort Point Capital Partners's 13F filing for Q1 2022, filed 13 May 2022.